Familial gigantism de Herder WW insulinoma. Nature. 1988;332(3):85–7, http://dx.doi.org/10.1038/ 332085a0. 58. Teh BT, Kytola S, Farnebo F, H o¨o¨ g A, Kyto¨ la¨ S, Korpi-Hyo¨ va¨lti E, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab. 1998;83(8):2621–6, http://dx.doi.org/10.1210/ jc.83.8.2621. 59. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87(2):457–65, http://dx.doi.org/10.1210/jc.87.2.457. 60. Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J Clin Endocrinol Metab. 2000;85(10):3860–5, http://dx.doi.org/10.1210/jc.85.10.3860. 61. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26(1):89–92, http://dx.doi.org/10.1038/79238. 62. Vasilev V, Daly AF, Petrossians P, Zacharieva S, Beckers A. Familial pituitary tumor syndromes. Endocr Pract. 2011;17(Suppl 3):41–6, http:// dx.doi.org/10.4158/EP11064.RA. 63. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):543–54, http://dx.doi.org/10.1016/j.beem.2009.05.008. CLINICS 2012;67(S1):29-32 64. Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419–27, http://dx.doi.org/10.1016/j.tem.2010.02.007. 65. Pinho LK, Vieira NL, Wildemberg LE, Moraes AB, Takiya CM, Frohman LA, et al. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. Arq Bras Endocrinol Metabol. 2010;54(8):698–704, http://dx.doi.org/10.1590/S0004- 27302010000800006. 66. Ozfirat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol. 2010;326(1–2):71–9, http://dx.doi.org/ 10.1016/j.mce.2010.05.001. 67. Daly AF, Tichomirowa MA, Petrossians P, Helio¨ vaara E, Jaffrain-Rea ML, Barlier A, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373–83, http://dx.doi.org/10.1210/jc.2009-2556. 68. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi CL, Yaneva M, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165(4):509–15, http://dx.doi.org/10.1530/EJE-11- 0304. 69. Chahal HS, Stals K, Unterlander M, Balding DJ, Thomas MG, Kumar AV, et al. AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med. 2011;364(1):43–50, http://dx.doi.org/10.1056/ NEJMoa1008020. 32